Yahoo! Finance: PTN News

Latest Financial News for PALATIN TECH INC

• New Star Analyst Rankings for PALATIN TECH INC (StarMine)

  (Tue, 18 Nov 2008 14:23:39 Etc/GMT)

• Palatin Technologies Earnings Call scheduled for 11:00 am ET today (CCBN)

  (Mon, 17 Nov 2008 16:00:00 Etc/GMT)

• Palatin Technologies, Inc. Reports Fiscal Year 2009 First Quarter Results; Teleconference and Webcast To Be Held on November 17, 2008 (PR Newswire)

  (Mon, 17 Nov 2008 12:30:00 Etc/GMT)

  Palatin Technologies, Inc. announced today results for its first quarter ended September 30, 2008.

• PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report (EDGAR Online)

  (Fri, 14 Nov 2008 21:38:23 Etc/GMT)

• Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008 (PR Newswire)

  (Thu, 13 Nov 2008 15:06:00 Etc/GMT)

  Palatin Technologies, Inc. will announce its first quarter, fiscal year 2009 financial results on Monday, November 17, 2008 before the open of the U.S. financial markets.

• PALATIN TECHNOLOGIES INC Financials (EDGAR Online Financials)

  (Sat, 4 Oct 2008 13:04:19 Etc/GMT)

• Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008 (PR Newswire)

  (Tue, 30 Sep 2008 15:36:00 Etc/GMT)

  Palatin Technologies, Inc. will discuss the fourth quarter and year end financial results for the fiscal year ended June 30, 2008 and provide an update on corporate developments during a conference call and webcast on September 30, 2008 at 11:15 a.m.

• Palatin Technologies Earnings Call scheduled for 11:00 am ET today (CCBN)

  (Tue, 30 Sep 2008 15:00:00 Etc/GMT)

• PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition (EDGAR Online)

  (Tue, 30 Sep 2008 13:54:22 Etc/GMT)

• Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2008 Results; Teleconference and Webcast to be held on September 30, 2008 (PR Newswire)

  (Tue, 30 Sep 2008 11:30:00 Etc/GMT)

  Palatin Technologies, Inc. announced today results for its fourth quarter and fiscal year ended June 30, 2008.

Yahoo! Finance: PTN Financial Blogs

Latest Financial Financial Blogs for PALATIN TECH INC

MSN Money News - PTN

News about Palatin Technologie Inc

• Palatin Technologies to Report Fiscal Year 2009 F

  (Thursday, November 13, 2008 10:06 AM)

  CRANBURY, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Palatin Technologies,

PTN - News and Analysis from Seeking Alpha

'PTN' Tag RSS Syndication from SeekingAlpha.com

• Palatin Technologies, Inc. F4Q08 (Qtr End 06/30/08) Call Transcript

  (Tue, 30 Sep 2008 17:55:28 -0400)

  Palatin Technologies, Inc. (PTN)

  F4Q08 Earnings Call

  
  Complete Story »

• Biotech Day In Review: AstraZeneca Enters Two Partnerships Worth $800 Million

  (Thu, 01 Feb 2007 04:45:06 -0500)

  AstraZeneca (AZN) signed two drug development deals, both of which start small, but have the potential to become significant. The first was with a privately held British biotech called Argenta Discovery, which could be worth up to $500 million.

  The two companies will collaborate to develop better bronchodilators that treat chronic obstructive pulmonary disease, also called smoker?s lung. AstraZeneca will make a $21 million upfront payment to Argenta and underwrite research, which is currently in the pre-clinical stage, into LAMA and MABA drugs that could be once-daily therapies. Human trials are at least a year off. AstraZeneca rose 40 cents...

• Earnings Schedule & Estimates for Wednesday, September 13, 2006

  (Wed, 13 Sep 2006 06:36:42 -0400)

  

  Aastrom Biosciences Inc. (ASTM)
  FQ4 2006 Revenue Estimate: $160.00K
  FQ4 2006 EPS Estimate: $-0.04
  FQ1 2007 Revenue Estimate: $240.00K
  FQ1 2007 EPS Estimate: $-0.04
  FQ3 2006 reported on 05/10/06
  EPS Estimate: -$0.04 ¦ EPS Actual: ($0.04)
  05/10/06 Close: $1.53 Change($): $0.03 Change(%): 2.0%
  05/11/06 Close: $1.41 Change($): ($0.12) Change(%): -8.5%

  
  Complete Story »

• Palatin Tech: Developing a New Aphrodesiac? (PTN, KG)

  (Mon, 01 May 2006 04:22:13 -0400)

  David Phillips (10Q Detective) submits: Melanocortin receptors [MC] are involved in the control of endocrine, autonomic and central nervous system functions. To date, five MC receptors subtypes have been identified. Targeting MC family of receptors provides therapeutic opportunities to treat a variety of conditions and diseases, including sexual dysfunction, obesity, cachexia (extreme wasting, generally secondary to a chronic disease) and inflammation. The 10Q Detective believes that MC-based therapeutics is one of the fastest growing areas of pharmaceutical research and development.

  Palatin Technologies,...

Investor Clicks Financial Advertising

News for Palatin Technologies, Inc. - Google Finance

News for Palatin Technologies, Inc. - Google Finance

• Palatin Technologies, Inc. Reports Fiscal Year 2009 First Quarter Results; Teleconference and Webcast To Be Held on November 17, 2008

  (Mon, 17 Nov 2008 14:05:28 GMT)
  Palatin Technologies, Inc. Reports Fiscal Year 2009 First Quarter Results; Teleconference and Webcast To Be Held on November 17, 2008
  PR Newswire (press release) - Nov 17, 2008

  CRANBURY, NJ, Nov. 17 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX: PTN) announced today results for its first quarter ended September 30, 2008. Palatin reported a net loss of $4.3 ...

• Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008

  (Thu, 13 Nov 2008 19:05:42 GMT)
  Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
  PR Newswire (press release) - Nov 13, 2008

  CRANBURY, NJ, Nov. 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX: PTN) will announce its first quarter, fiscal year 2009 financial results on Monday, November 17, 2008 before the ...

• Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008

  (Thu, 13 Nov 2008 15:11:50 GMT)
  Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
  PR Newswire (press release) - Nov 13, 2008

  CRANBURY, NJ, Nov. 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) will announce its first quarter, fiscal year 2009 financial results on Monday, November 17, 2008 before the ...

• Business Briefs

  (Fri, 03 Oct 2008 04:36:06 GMT)
  Business Briefs
  The Times of Trenton - NJ.com - Oct 3, 2008

  PENNINGTON -- Ocean Power Technologies, which generates power from ocean waves and specially made buoys, has received a $2 million award from the Department of Energy toward a project off the ...

• Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008

  (Tue, 30 Sep 2008 19:05:09 GMT)
  Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
  PR Newswire (press release) - Sep 30, 2008

  CRANBURY, NJ, Sept. 30 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX: PTN) will discuss the fourth quarter and year end financial results for the fiscal year ended June 30, 2008 and ...

• Palatin Tech. Q4 Loss Narrows - Update

  (Tue, 30 Sep 2008 12:35:09 GMT)
  Palatin Tech. Q4 Loss Narrows - Update
  RTT News - Sep 30, 2008

  (RTTNews) - Tuesday, Palatin Technologies, Inc. (PTN: News ), a biopharmaceutical company, reported a narrower loss for the fourth quarter than last year, helped by the reduction in development ...

• Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2008 Results; Teleconference and Webcast to be held on September 30, 2008

  (Tue, 30 Sep 2008 11:46:42 GMT)
  Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2008 Results; Teleconference and Webcast to be held on September 30, 2008
  PR Newswire (press release) - Sep 30, 2008

  CRANBURY, NJ, Sept. 30 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) announced today results for its fourth quarter and fiscal year ended June 30, 2008. Palatin reported a net ...

  Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008 - Earthtimes (press release)
  

• FirstAlert: 3:45 AM-5 PM Investrend / Bestcalls

  (Tue, 30 Sep 2008 01:08:57 GMT)
  FirstAlert: 3:45 AM-5 PM Investrend / Bestcalls
  Trading Markets (press release) - Sep 30, 2008

  Sep 30, 2008 (financialwire.net via COMTEX) -- XRTX | Quote | Chart | News | PowerRating -- September 30, 2008 (Financial Wire) Conference calls scheduled at 3:45 am to 5 pm on Investrend ...

• Palatin Technologies to Report Fourth Quarter and Fiscal Year End 2008 Financial Results; Conference Call and Webcast on September 30, 2008

  (Thu, 25 Sep 2008 14:06:22 GMT)
  Palatin Technologies to Report Fourth Quarter and Fiscal Year End 2008 Financial Results; Conference Call and Webcast on September 30, 2008
  PR Newswire (press release) - Sep 25, 2008

  CRANBURY, NJ, Sept. 25 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX: PTN) will announce its fourth quarter and fiscal year end 2008 financial results on September 30, 2008 before the ...

• Palatin Technologies Presents PL-3994 Clinical Trial Results At The 12th Annual Scientific Meeting Of The Heart Failure Association Of America

  (Wed, 24 Sep 2008 07:07:45 GMT)
  Palatin Technologies Presents PL-3994 Clinical Trial Results At The 12th Annual Scientific Meeting Of The Heart Failure Association Of America
  Medical News Today (press release) - Sep 24, 2008

  Palatin Technologies, Inc. (Amex: PTN) announced it presented results from a Phase 1 clinical study with PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under ...

  Palatin Technologies's Phase I heart failure trial meets endpoint - Trading Markets (press release)
  Palatin Technologies's Phase I Heart Failure Trial Meets Endpoint - RedOrbit
  

MarketWatch.com - All MarketWatch News - PTN

MarketWatch, a leading publisher of business and financial news, offers users up-to-the minute news, investment tools, and subscription products.

• Biotech Stocks: Wyeth gains; benchmarks make narrow moves

  (Thu, 27 Sep 2007 03:33:00 -0500)

  NEW YORK (MarketWatch) -- Drug shares rose in Thursday afternoon trading, and Wyeth traded higher after the company announced a new chief executive and an increase in the share buyback plan.

• Drug and biotech shares rise, Palatin jumps on data

  (Thu, 27 Sep 2007 09:47:08 -0500)

  NEW YORK (MarketWatch) - Drug and biotech shares rose in Thursday morning trading, boosted by Forest Labs and Enzon Pharmaceuticals . Shares of Palatin Technologies Inc. jumped 10% after the company announced results from an at-home Phase II trial evaluating bremelanotide for the treatment of female sexual arousal disorder. The Amex Pharmaceutical Index was up fractionally at 347.80, while the Amex Biotechnology Index rose to 825.84.

• Movers & Shakers: Thursday's biggest stock gainers and decliners

  (Thu, 30 Aug 2007 04:50:00 -0500)

  Thursday's biggest stock gainers and decliners

• Biotech Stocks: Palatin plunges on drug setback; Atherogenics continues rally

  (Thu, 30 Aug 2007 01:42:00 -0500)

  BOSTON (MarketWatch) -- Biotech stocks traded generally higher Thursday, but shares of Palatin Technologies plunged more than 60% in reaction to plans to delay Phase III testing for a prospective erectile-dysfunction drug over safety concerns voiced by regulators.

• King Pharma, Palatin to delay ED candidate's Phase III testing

  (Thu, 30 Aug 2007 08:53:00 -0500)

  BOSTON (MarketWatch) -- King Pharmaceuticals and Palatin Technologies have delayed the launch of Phase III testing for an erectile-dysfunction drug candidate as a result of regulatory concerns, the said Thursday.

• Palatin Tech, King Pharmaceutical Delay Phase III Bremelanotide Trial

  (Thu, 30 Aug 2007 08:22:00 -0500)

  Palatin Technologies Inc. and King Pharmaceuticals Inc. delayed plans for Phase III clinical trials of bremelanotide, which treats male erectile dysfunction. The decision follows comment from the Food and Drug Administration, which raised concerns about the acceptable benefit/risk ratio to support the progression of the program into Phase III studies. After reviewing the data generated in the Phase I and Phase II studies, the FDA questioned the overall efficacy results and the clinical benefit of the product, and cited blood pressure increases as its greatest safety concern. Palatin and King plan to review the FDA comments to determine...

• King, Palatin trial delay due to FDA concerns

  (Thu, 30 Aug 2007 08:10:17 -0500)

• King, Palatin delay erectile drug phase-III trial

  (Thu, 30 Aug 2007 08:09:58 -0500)

• Biotech Stocks: Drug stocks gain, Bristol-Myers climbs on takeover talk

  (Wed, 31 Jan 2007 04:20:00 -0500)

  BOSTON (MarketWatch) -- Drug stocks closed higher Wednesday as shares of Bristol-Myers Squibb Co. gained on reports that the company has hired three leading banks to advise it on a possible takeover bid.

• Palatin Tech to place 11 units at $2.44 each

  (Wed, 12 Apr 2006 07:51:27 -0500)

  NEW YORK (MarketWatch) - Palatin Technologies Inc. said Wednesday it signed an agreement to sell 11 million units at $2.44 each for a total of about $27 million. The Cranbury, N.J., biopharmaceutical company said each unit will comprise one common share share and one warrant to purchase 0.30 share of common stock at $2.44 a unit. The warrants have a five-year term and an exercise price of $2.88 a share. Shares of Palatin closed Tuesday at $2.35.

Only registered users can write comments.
Please login or register.

---